InfraReDx Report issue

For profit Phase 2
Founded: Burlington MA United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2013
NCT01837823
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

InfraReDx (indirect)

Active Ingredients

Drugs in Phase 2 Trials (1)

rosuvastatin (crestor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Inflammation (Phase 2)

Myocardial Ischemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1